Nanjing King-Friend

Building on that foundation, Kingfriend masters novel drug delivery systems – nano fat emulsions (commercial‑scale, BE‑ready), liposomes (unilamellar and multivesicular), USFDA‑approved inclusion complexes, and nanoparticles. All under international cGMP, these technologies enhance bioavailability, reduce toxicity, and extend product lifecycle.

NKF Receives US FDA Approval for High-Concentration YUSIMRY Formulation

NKF announced U.S. FDA approval for a high-concentration formulation of YUSIMRY (adalimumab-aqvh), expanding its U.S. biologics business.

NKF’s independently developed Propofol Injectable Emulsion received U.S. FDA ANDA approval for general anesthesia and sedation, covering 200mg/20mL, 500mg/50mL, and 1000mg/100mL.

Adhering to our people-oriented talent strategy, we grow alongside our people. As a company expanding globally, we offer broad, open career paths and a stage to realize your full potential, paired with competitive benefits.

We are committed to creating a diverse, equal and inclusive working environment, respecting the uniqueness of each employee, providing fair development opportunities, and promoting collaboration and innovation among employees from different backgrounds.

The above market information is provided by the Shanghai Stock Exchange (SSE). All data is subject to a time delay and is for reference only.

King-friend is a fast growing biochemcial pharmaceutical company, dedicating to build a global pharmaceutical platform with integration of R&D, CMC, Regulatory and sales, and leading the globalization of Chinese companies.

Unless otherwise expressly stated, all content is owned by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. All rights reserved.